| abstract |
I) determining the protein concentration of one, two, three, four, five or six members, or mixtures or combinations thereof, of the complement factor H family in a sample of a patient; ii) the protein concentration determined in step i) is one, two, three, four, five or six members of the complement factor H family in patients with neurodevelopmental, neurological or neuropsychiatric disorders. Comparing the representative value of the protein concentration of; iii) higher protein concentrations of one, two, three, four, five or six members from the complement factor H family in samples of patients with neurodevelopmental, neurological or neuropsychiatric disorders. Indicating a patient to obtain clinical benefit from treatment with a compound targeting a glutamate neurotransmission pathway; And iv) selecting a therapy for a patient suffering from a neurodevelopmental disorder, a neurological disorder or a neuropsychiatric disorder, when treated with a compound targeting a glutamate neurotransmitter pathway, It relates to an in vitro method for predicting a response to a patient suffering from a mental disorder. |